Starpharma Receives USD $5.5 Million Upfront Payment from Genentech

Starpharma Holdings Limited (ASX: SPL) has announced the receipt of an upfront payment of USD $5.5 million (AUD $8.5 million) from Genentech, a member of the Roche Group, following the recently established license agreement between the two companies. This collaboration marks the commencement of a development program using Starpharma’s proprietary DEP® dendrimer platform to create dendrimer-drug conjugates incorporating Genentech’s oncology medicines.

The agreement also includes potential development, commercial, and sales milestone payments of up to USD $564 million (AUD $869 million), along with tiered royalties on global net sales. Starpharma’s DEP® technology offers key benefits such as enhanced solubility, improved efficacy, controlled pharmacokinetics, and reduced toxicity. Its broad applicability across small molecules, peptides, proteins, and advanced therapeutic classes provides opportunities for partners to enhance product performance, expand treatment indications, and strengthen their pharmaceutical pipelines.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com